Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders

Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders

Summary. With symptomatic remission and functional recovery as the overarching therapeutic objectives of antidepressant therapy, composite endpoint measures that conjointly consider both aspects of treatment are needed. This analysis evaluated the combined eﬀect of vortioxetine on depressive symptom...

Full description

Bibliographic Details
Main Authors:	М. С. Christensen, Н. Loft, R. S. McIntyre
Format:	Article
Language:	Russian
Published:	Federal State Budget Scientific Institution National Medical Research Center for Psychiatry and Neurology n.a. V.M. Bekhterev Ministry of Health of the Russian Federation 2019-07-01
Series:	Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева
Online Access:	https://www.bekhterevreview.com/jour/article/view/250

Similar Items

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
by: Bing Cao, et al.
Published: (2019-01-01)

Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
by: McIntyre RS, et al.
Published: (2021-02-01)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
by: Zuzana Mlyncekova, et al.
Published: (2023-10-01)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
by: Xinyan Zhang, et al.
Published: (2022-06-01)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
by: Kelliny M, et al.
Published: (2015-08-01)

Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine
by: Mehala Subramaniapillai, et al.
Published: (2019-10-01)

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects
by: Eugenia Papalexi, et al.
Published: (2022-08-01)

Efficiency and safety of Vortioxetine in the treatment of depressive disorders in cardiac patients
by: N. V. Filippova, et al.
Published: (2023-06-01)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
by: Shihong Xiong, et al.
Published: (2022-06-01)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
by: Basurte-Villamor I, et al.
Published: (2022-05-01)

Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
by: Pratap Chokka, et al.
Published: (2021-05-01)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
by: De Filippis S, et al.
Published: (2022-08-01)

The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change
by: Roger S. McIntyre, et al.
Published: (2020-06-01)

Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study
by: Hong Kim, et al.
Published: (2022-03-01)

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study
by: Domenico De Berardis, et al.

Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report
by: Yusei Yamaguchi, et al.
Published: (2024-03-01)

Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results
by: Oppa M., et al.
Published: (2017-09-01)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study
by: Polosan M, et al.
Published: (2022-08-01)

Vortioxetine usage in an elderly patient with major depressive disorder and accompanied by multiple physical conditions: A case report
by: Xiaoman Wang, et al.
Published: (2023-12-01)

Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report
by: Orkun Aydin, et al.
Published: (2018-01-01)

Practical Advice for Primary Care Clinicians on the Safe and Effective Use of Vortioxetine for Patients with Major Depressive Disorder (MDD)
by: Montano CB, et al.
Published: (2022-04-01)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
by: Cristina Segura-Garcia, et al.
Published: (2021-03-01)

A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder
by: Baskaran A, et al.
Published: (2013-01-01)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
by: Gregory Mattingly, et al.
Published: (2023-01-01)

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea
by: Seok Woo Moon, et al.
Published: (2023-03-01)

Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
by: Maggie McCue, et al.
Published: (2022-06-01)

Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
by: Eduardo Cumbo, et al.
Published: (2023-01-01)

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
by: Djamila Bennabi, et al.
Published: (2019-11-01)

Religious coping as a predictor of outcome in major depressive disorder
by: Lakhan R Kataria, et al.
Published: (2016-01-01)

Predictive potential of somatic symptoms for the identification of subthreshold depression and major depressive disorder in primary care settings
by: Xiuwen Li, et al.
Published: (2023-02-01)

Experience with vortioxetine in the treatment of post-stroke depression
by: I. A. Strelnikova, et al.
Published: (2020-02-01)

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
by: Wang G, et al.
Published: (2022-08-01)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
by: Diego Santos García, et al.
Published: (2022-10-01)

A Case of Major Depression with Burning Mouth Syndrome and Tinnitus Successfully Treated with Vortioxetine
by: Yoshimura R, et al.
Published: (2021-04-01)

Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey
by: Subhara Raveendran, et al.
Published: (2023-06-01)

Major Depressive Disorder
by: G Grobler
Published: (2013-08-01)

Clinical features and treatment outcomes of major depressive disorder with genital symptoms
by: Xiaohui Wu, et al.
Published: (2024-03-01)

Executive Subdomains Are Differentially Associated With Psychosocial Outcomes in Major Depressive Disorder
by: Matthew J. Knight, et al.
Published: (2018-07-01)

Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder
by: Danfeng Yan, et al.
Published: (2021-08-01)

The efficacy of vortioxetine for the delusional disorder of cenesthopathy
by: Shinji Sato, et al.
Published: (2024-03-01)